PerkinElmer, Inc. (NYSE:PKI) disclosed that it has received the Food and Drug Administration’s emergency use authorization for its coronavirus RT-PCR test.
The company, based in Waltham, Mass., declared linical laboratories certified under Clinical Laboratory Improvement Amendments can immediately begin using this kit to detect SARS-CoV-2, the virus that causes COVID-19. PerkinElmer’s RT-PCR test is marketed as an in vitro diagnostic device by meeting
Said CEO Prahlad Singh, "Despite the challenging environment, our employees have demonstrated unwavering commitment over the past two months to combat this global pandemic.
"The breadth of PerkinElmer’s total workflow solution puts us in a unique position to rapidly address the needs of our clinical diagnostics customers."
According to the company website, "PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets.
"We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally."
Perkin shares jumped $2.96, or 4%, to $77.27
